PEG-Interferon Alpha Stabilization via Lyophilization

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current formulations of PEG-Interferon alpha 2b are unstable in liquid form and require long lyophilization cycles, leading to increased manufacturing costs and higher moisture content, necessitating the development of novel lyophilized and stabilized formulations that can maintain stability during and after lyophilization and support long-term storage at room temperature.

Innovation Solution

The development of novel lyophilized and stabilized formulations of PEG-Interferon alpha conjugates using suitable buffers, cryoprotectants, stabilizers, and solvents, such as sodium succinate, lactose, trehalose, and polysorbate 80, which are lyophilized to create a stable dry powder that can be reconstituted for use, reducing lyophilization time and enhancing cost-effectiveness.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If PEG-Interferon alpha 2b is formulated in liquid form, then it maintains biological activity, but it becomes unstable and requires frequent administration

Engineering Contradiction:
ImprovestabilityVSAvoidstorage duration
Core Design Contradiction:
ReliabilityVSDuration of action of stationary object

Solution Approach 1:

The patent applies freeze-drying (lyophilization) to transition the formulation from liquid to solid frozen state, then to dry powder form. This phase transition removes water that causes instability, allowing the PEG-Interferon alpha conjugate to be stored stably at room temperature for extended periods while maintaining biological activity upon reconstitution

Inventive Principle:
Principle #36Phase transitions

Solution Approach 2:

The patent incorporates stabilizers and cryoprotectants in the formulation before lyophilization to protect the PEG-Interferon alpha conjugate from degradation during the freeze-drying process and during storage. These protective agents cushion the protein from structural damage and prevent aggregation, ensuring stability is maintained throughout the formulation process and storage period

Inventive Principle:
Principle #11Beforehand cushioning (Prior cushioning)

2Reliability

If conventional lyophilization is used for PEG-Interferon alpha 2b, then stability is improved, but manufacturing time and costs increase

Engineering Contradiction:
ImprovestabilityVSAvoidlyophilization time
Core Design Contradiction:
ReliabilityVSLoss of time

Solution Approach 1:

The patent optimizes lyophilization parameters including temperature profiles, pressure conditions, and formulation composition to achieve faster drying cycles. By carefully controlling these parameters and using appropriate stabilizers, the patent reduces manufacturing time while maintaining product stability and quality

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

The patent performs preliminary optimization of the formulation composition and lyophilization protocol to establish efficient manufacturing parameters in advance. This preliminary work enables shorter, more predictable lyophilization cycles during production while ensuring consistent product quality and stability

Inventive Principle:
Principle #10Preliminary action

3Reliability

If conventional lyophilization is used for PEG-Interferon alpha 2b, then stability is improved, but moisture content increases

Engineering Contradiction:
ImprovestabilityVSAvoidmoisture content
Core Design Contradiction:
ReliabilityVSLoss of substance

Solution Approach 1:

The patent uses freeze-drying to completely remove water from the formulation by sublimating ice directly to vapor under vacuum. This phase transition ensures minimal residual moisture content in the final dry powder product, preventing hydrolysis and degradation reactions that would compromise stability during storage

Inventive Principle:
Principle #36Phase transitions

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The new formulations provide improved stability and physical strength, reducing the risk of depegylation and moisture content, resulting in a more cost-effective and efficient manufacturing process with shorter lyophilization cycles, while maintaining the biologically active form of the PEG-Interferon alpha conjugates for extended periods.

Implementation Method 1

The formulations involve formulating PEG-Interferon alpha conjugates with suitable buffer(s), suitable cryoprotectant(s), suitable stabilizer(s) and a solvent, optionally with other suitable excipients, which is subsequently lyophilized

Methodology Applied
Scientific EffectCryoprotection:

Implementation Method 2

which is subsequently lyophilized

Methodology Applied
Scientific EffectLyophilization: Freeze Drying

Implementation Method 3

The formulations involve formulating PEG-Interferon alpha conjugates with suitable buffer(s), suitable cryoprotectant(s), suitable stabilizer(s) and a solvent, optionally with other suitable excipients, which is subsequently lyophilized

Methodology Applied
Scientific EffectLyophilization: Freeze Drying

Data Source

PatentEP2097068B1Formulations of peg-interferon alpha conjugates
Publication Date: 2013.09.04 ZYDUS LIFESCIENCES LTD

AI summary

The present invention relates to novel lyophilized and stabilized formulations of PEG-Interferon alpha conjugates and the process for their preparation. The novel formulations of PEG-Interferon alpha conjugates reported by the inventors of this application requires less lyophilization cycle and are more cost competitive.